NIH botched biolab safety study: NRC

The NIH's safety assessment of a linkurl:controversial Boston University laboratory;http://www.the-scientist.com/news/display/24679/ did not thoroughly develop worst case scenarios or adequately compare safety risks at other proposed sites, finds a linkurl:National Research Council report.;http://www.nap.edu/catalog.php?record_id=12073 The council released its 28-page report yesterday (November 29th) after the Massachusetts government commissioned it to review the NIH appraisal, which had linku

kerry grens
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share
The NIH's safety assessment of a linkurl:controversial Boston University laboratory;http://www.the-scientist.com/news/display/24679/ did not thoroughly develop worst case scenarios or adequately compare safety risks at other proposed sites, finds a linkurl:National Research Council report.;http://www.nap.edu/catalog.php?record_id=12073 The council released its 28-page report yesterday (November 29th) after the Massachusetts government commissioned it to review the NIH appraisal, which had linkurl:concluded;http://www.nems.nih.gov/aspects/nat_resources/programs/nepa2.cfm in July 2007 that the site chosen to build the laboratory was the safest among three possible sites. But according to the council's report, "The conclusions reached in the [NIH] report are not adequately supported by the analyses." The linkurl:biodefense laboratory,;http://www.the-scientist.com/news/display/23076/ which will include a linkurl:Biosafety Level 4 facility,;http://www.the-scientist.com/news/display/53626 has faced linkurl:opposition;http://www.the-scientist.com/news/display/23468 from residents in the South End area of Boston where the lab is being built. Yesterday's report concluded that the NIH assessment did not use appropriate pathogens in its models of worst case scenarios. "A more suitable analysis would have included the selection of agents that are more transmissible and thus might have created a greater risk of urban outbreaks," the council's report states. The NIH's report also did not specify the assumptions made in determining worst case scenario models, John Ahearne, emeritus director of the ethics program at Sigma Xi, said in a press release. According to the __Boston Globe's__ linkurl:report;http://tinyurl.com/yt6zvx today, opponents hope the council's report will help sway judges who are considering whether or not the lab should open.
Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Meet the Author

  • kerry grens

    Kerry Grens

    Kerry served as The Scientist’s news director until 2021. Before joining The Scientist in 2013, she was a stringer for Reuters Health, the senior health and science reporter at WHYY in Philadelphia, and the health and science reporter at New Hampshire Public Radio. Kerry got her start in journalism as a AAAS Mass Media fellow at KUNC in Colorado. She has a master’s in biological sciences from Stanford University and a biology degree from Loyola University Chicago.

Share
3D illustration of a gold lipid nanoparticle with pink nucleic acid inside of it. Purple and teal spikes stick out from the lipid bilayer representing polyethylene glycol.
February 2025, Issue 1

A Nanoparticle Delivery System for Gene Therapy

A reimagined lipid vehicle for nucleic acids could overcome the limitations of current vectors.

View this Issue
Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

sartorius logo
Considerations for Cell-Based Assays in Immuno-Oncology Research

Considerations for Cell-Based Assays in Immuno-Oncology Research

Lonza
An illustration of animal and tree silhouettes.

From Water Bears to Grizzly Bears: Unusual Animal Models

Taconic Biosciences
Sex Differences in Neurological Research

Sex Differences in Neurological Research

bit.bio logo

Products

Tecan Logo

Tecan introduces Veya: bringing digital, scalable automation to labs worldwide

Explore a Concise Guide to Optimizing Viral Transduction

A Visual Guide to Lentiviral Gene Delivery

Takara Bio
Inventia Life Science

Inventia Life Science Launches RASTRUM™ Allegro to Revolutionize High-Throughput 3D Cell Culture for Drug Discovery and Disease Research

An illustration of differently shaped viruses.

Detecting Novel Viruses Using a Comprehensive Enrichment Panel

Twist Bio